Cargando…

Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis

INTRODUCTION: Atopic dermatitis (AD) is associated with significant quality-of-life and economic burdens. Real-world evidence is needed to identify optimal treatment pathways for AD. Here we evaluate real-world effectiveness of systemic therapies for moderate-to-severe AD in the USA. METHODS: Data (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jashin J., Lafeuille, Marie-Hélène, Emond, Bruno, Fakih, Iman, Duh, Mei Sheng, Cappelleri, Joseph C., Yin, Natalie, Feeney, Claire, Myers, Daniela E., DiBonaventura, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402759/ https://www.ncbi.nlm.nih.gov/pubmed/35821555 http://dx.doi.org/10.1007/s12325-022-02197-z

Ejemplares similares

Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis
por: Wu, Jashin J., et al.
Publicado: (2021)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
por: Silverberg, J.I., et al.
Publicado: (2021)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Economic Burden of Atopic Manifestations in Patients With Atopic Dermatitis - Analysis of Administrative Claims
por: Suh, Dong-Churl, et al.
Publicado: (2007)

Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review
por: Silverberg, J.I., et al.
Publicado: (2022)

Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis
por: Kwatra, Shawn G., et al.
Publicado: (2021)

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases
por: Ortsäter, Gustaf, et al.
Publicado: (2022)

Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis
por: Hagenström, Kristina, et al.
Publicado: (2021)

Epidemiology and Characterization of Atopic Dermatitis in East Asian Populations: A Systematic Review
por: Cheng, Julia, et al.
Publicado: (2021)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases
por: Shrestha, Sulena, et al.
Publicado: (2017)

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020)

The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
por: Girolomoni, Giampiero, et al.
Publicado: (2020)

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
por: Meyers, Kristin J., et al.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral
por: Egeberg, Alexander, et al.
Publicado: (2021)

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
por: Ständer, Sonja, et al.
Publicado: (2022)

Sleep patterns of young children with newly diagnosed atopic dermatitis
por: Dogan, Derya Gumus, et al.
Publicado: (2017)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

Health‐care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis
por: Igarashi, Atsuyuki, et al.
Publicado: (2019)

The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study
por: Wu, Jashin J., et al.
Publicado: (2022)

Prescription Market Share and Treatment Patterns in Atopic Dermatitis: A Retrospective Observational Study Using US Insurance Claims
por: Fenske, Christian, et al.
Publicado: (2022)

Patient Journey in Atopic Dermatitis: The Real-World Scenario
por: Carrascosa, Jose Manuel, et al.
Publicado: (2021)

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents
por: Ständer, S., et al.
Publicado: (2022)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?
por: Gaspar, Neide Kalil, et al.
Publicado: (2016)

Real-world treatment patterns for atopic dermatitis in South Korea
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Relationship Among Treatment, Pruritus, Investigator’s Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis
por: Simpson, Eric L., et al.
Publicado: (2021)

Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol
por: de Lusignan, Simon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5il64vd4psphdb9c52g3on14o2